Mepolizumab Reduced Severe Asthma
Exacerbations by 50%
In the largest study to date, the monoclonal antibody mepolizumab showed promise in reducing severe exacerbations of asthma. The results hold out the possibility of an effective alternative to oral corticosteroids and their side effects. Pharmacists might be surprised by how effective mepolizumab was in reducing emergency visits and hospitalizations.
Here are the details.